meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus SoC